Skip to content

Metabonomics based clinical study of post-transjugular intrahepatic portosystemic shunt heaptic encephalopathy in liver cirrhosis

Clinical studies of alternations of human internal environment and risk prediction of adverse events subsequent to transjugular intrahepatic portosystemic shunt in liver cirrhosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000039616
Enrollment
Unknown
Registered
2020-11-03
Start date
2020-11-09
Completion date
Unknown
Last updated
2021-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis

Interventions

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. Patients diagnosed with cirrhosis; 3. Patients undergoing elective TIPS.

Exclusion criteria

Exclusion criteria: 1. Patients who had undergone tips or surgical shunt in the past; 2. Patients with previous history of hepatic encephalopathy, or diagnosed with hepatic encephalopathy at the time of inclusion; 3. Patients with hepatic myelopathy and other neuropsychiatric diseases; 4. Patients who used nutrition, antibiotics or lactulose within 4 weeks before operation; 5. Patients with liver cirrhosis complications such as gastrointestinal bleeding, spontaneous peritonitis, hepatorenal syndrome and hepatopulmonary syndrome that are not controlled or stable for less than 1 week; 6. Patients with heart, lung, kidney, brain and other major organ dysfunction; 7. Patients whose vision impairment affects reading; 8. People with very low education level can't read and write simple words; 9. Subjects from high altitude (> 2500 m); 10. Pregnant and lactating women; 11. In patients with child score over 12, transaminase was 5 times higher than the upper limit of normal 12. Patients with cholestatic liver disease (primary biliary cholangitis, primary sclerosing cholangitis and extrahepatic bile duct obstruction, etc.); 13. Patients with malignant tumor; 14. Cavernous transformation of portal vein.

Design outcomes

Primary

MeasureTime frame
Metabonomics;hepatic encephalopathy;

Countries

China

Contacts

Public ContactHuan Tong

West China Hospital of Sichuan University

doctortonghuan@163.com+86 28-85423387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026